The SGLT2 Inhibitor Dapagliflozin Ameliorates Renal Fibrosis in Hyperuricemic Nephropathy

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2024 Aug 21

PMID 39168099

Authors

Hongtu Hu

Weiwei Li

Yiqun Hao

Zhuan Peng

Zhengping Zou

Jiali Wei

Ying Zhou

Wei Liang

Yun Cao

Affiliations

Soon will be listed here.

Abstract

Hyperuricemic nephropathy (HN) is a global metabolic disorder characterized by uric acid (UA) metabolism dysfunction, resulting in hyperuricemia (HUA) and tubulointerstitial fibrosis (TIF). Sodium-dependent glucose transporter 2 inhibitor, dapagliflozin, has shown potential in reducing serum UA levels in patients with chronic kidney disease (CKD), though its protective effects against HN remain uncertain. This study investigates the functional, pathological, and molecular changes in HN through histological, biochemical, and transcriptomic analyses in patients, HN mice, and UA-stimulated HK-2 cells. Findings indicate UA-induced tubular dysfunction and fibrotic activation, which dapagliflozin significantly mitigates. Transcriptomic analysis identifies estrogen-related receptor α (ERRα), a downregulated transcription factor in HN. ERRα knockin mice and ERRα-overexpressed HK-2 cells demonstrate UA resistance, while ERRα inhibition exacerbates UA effects. Dapagliflozin targets ERRα, activating the ERRα-organic anion transporter 1 (OAT1) axis to enhance UA excretion and reduce TIF. Furthermore, dapagliflozin ameliorates renal fibrosis in non-HN CKD models, underscoring the therapeutic significance of the ERRα-OAT1 axis in HN and CKD.

Citing Articles

Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization.

Xue L, Tao Q, Chang H, Yan S, Wang L, Zhao Z J Inflamm Res. 2025; 18():17-30.

PMID: 39780982 PMC: 11705990. DOI: 10.2147/JIR.S500101.

Metal-Dependent Cell Death in Renal Fibrosis: Now and in the Future.

Li T, Yu C Int J Mol Sci. 2025; 25(24.

PMID: 39769044 PMC: 11678559. DOI: 10.3390/ijms252413279.

Insights into renal damage in hyperuricemia: Focus on renal protection (Review).

Yang H, Ying J, Zu T, Meng X, Jin J Mol Med Rep. 2024; 31(3.

PMID: 39717954 PMC: 11711934. DOI: 10.3892/mmr.2024.13424.

References

Lin N, Homan K, Robinson S, Kolesky D, Duarte N, Moisan A . Renal reabsorption in 3D vascularized proximal tubule models. Proc Natl Acad Sci U S A. 2019; 116(12):5399-5404. PMC: 6431199. DOI: 10.1073/pnas.1815208116. View

Fathallah-Shaykh S, Cramer M . Uric acid and the kidney. Pediatr Nephrol. 2013; 29(6):999-1008. DOI: 10.1007/s00467-013-2549-x. View

Pou Casellas C, Jansen K, Rookmaaker M, Clevers H, Verhaar M, Masereeuw R . Regulation of solute carriers oct2 and OAT1/3 in the kidney: a phylogenetic, ontogenetic, and cell dynamic perspective. Physiol Rev. 2021; 102(2):993-1024. DOI: 10.1152/physrev.00009.2021. View

Crevet L, Vanacker J . Regulation of the expression of the estrogen related receptors (ERRs). Cell Mol Life Sci. 2020; 77(22):4573-4579. PMC: 11104921. DOI: 10.1007/s00018-020-03549-0. View

Eraly S, Hamilton B, Nigam S . Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun. 2002; 300(2):333-42. DOI: 10.1016/s0006-291x(02)02853-x. View

Vavra J, Mancikova A, Pavelcova K, Hasikova L, Bohata J, Stiburkova B . Functional Characterization of Rare Variants in OAT1/ and OAT3/ Urate Transporters Identified in a Gout and Hyperuricemia Cohort. Cells. 2022; 11(7). PMC: 8997829. DOI: 10.3390/cells11071063. View

Hayashi K, Mita K, Sawa T . Electroencephalographic changes in the late cardiopulmonary bypass period are not reflected in the bispectral index. Clin Neurophysiol. 2010; 121(8):1198-204. DOI: 10.1016/j.clinph.2010.03.018. View

He F, Ru X, Wen T . NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci. 2020; 21(13). PMC: 7369905. DOI: 10.3390/ijms21134777. View

Hirai T, Kawagoe Y, Kei M, Ogawa R, Itoh T . Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study. Biol Pharm Bull. 2020; 43(5):782-787. DOI: 10.1248/bpb.b19-00785. View

10.

McDowell K, Welsh P, Docherty K, Morrow D, Jhund P, de Boer R . Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail. 2022; 24(6):1066-1076. PMC: 9540869. DOI: 10.1002/ejhf.2433. View

11.

Mandal A, Mount D . The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2014; 77:323-45. DOI: 10.1146/annurev-physiol-021113-170343. View

12.

Beernink J, Persson F, Jongs N, Laverman G, Chertow G, McMurray J . Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care. 2023; 46(3):602-607. PMC: 10020024. DOI: 10.2337/dc22-1514. View

13.

Schneider R, Meusel M, Betz B, Held C, Moller-Ehrlich K, Buttner-Herold M . Oat1/3 restoration protects against renal damage after ischemic AKI. Am J Physiol Renal Physiol. 2014; 308(3):F198-208. DOI: 10.1152/ajprenal.00160.2014. View

14.

Crawley W, Jungels C, Stenmark K, Fini M . U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol. 2022; 51:102271. PMC: 8889273. DOI: 10.1016/j.redox.2022.102271. View

15.

Johnson R, Nakagawa T, Jalal D, Sanchez-Lozada L, Kang D, Ritz E . Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant. 2013; 28(9):2221-8. PMC: 4318947. DOI: 10.1093/ndt/gft029. View

16.

Euteneuer A, Seeger-Nukpezah T, Nolte H, Henjakovic M . Estrogen receptor α (ERα) indirectly induces transcription of human renal organic anion transporter 1 (OAT1). Physiol Rep. 2019; 7(21):e14229. PMC: 6854606. DOI: 10.14814/phy2.14229. View

17.

Narang R, Vincent Z, Phipps-Green A, Stamp L, Merriman T, Dalbeth N . Population-specific factors associated with fractional excretion of uric acid. Arthritis Res Ther. 2019; 21(1):234. PMC: 6852918. DOI: 10.1186/s13075-019-2016-6. View

18.

Chertow G, Vart P, Jongs N, Toto R, Gorriz J, Hou F . Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021; 32(9):2352-2361. PMC: 8729835. DOI: 10.1681/ASN.2021020167. View

19.

Schechter M, Jongs N, Chertow G, Mosenzon O, McMurray J, Correa-Rotter R . Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD. Ann Intern Med. 2022; 176(1):59-66. DOI: 10.7326/M22-2115. View

20.

Butt J, Docherty K, Claggett B, Desai A, Petersson M, Langkilde A . Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2023; 8(4):386-393. PMC: 9947801. DOI: 10.1001/jamacardio.2022.5608. View